![For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology](https://www.acc.org//-/media/Non-Clinical/Images/2020/04/CARDIOLOGY/FITs-Table-1-1200px.jpg)
For the FITs | Antiplatelet Therapy For High Bleeding Risk Patients Undergoing PCI - American College of Cardiology
![Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12928-022-00847-1/MediaObjects/12928_2022_847_Fig1_HTML.png)
Antiplatelet therapy after percutaneous coronary intervention: current status and future perspectives | SpringerLink
![Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020 Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020](https://journals.sagepub.com/cms/10.1177/2632463620953677/asset/images/large/10.1177_2632463620953677-fig2.jpeg)
Evolving Concepts in Post-PCI Antiplatelets Therapy - Kartik Pandurang Jadhav, Pankaj V. Jariwala, 2020
Dual antiplatelet therapy duration after percutaneous coronary intervention using drug eluting stents in high bleeding risk pati
![Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com](https://d18mqtxkrsjgmh.cloudfront.net/public/2019-09/Kirtane-EVOLVE.jpg)
Safe to Drop P2Y12 Inhibitor at 3 Months in High-Bleeding-Risk Patients: EVOLVE Short DAPT | tctmd.com
EVOLVE Short DAPT: A Single Arm Study of 3-Month DAPT in Patients at High Bleeding Risk Treated with a Bioabsorbable Polymer- Ba
![EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com](https://d18mqtxkrsjgmh.cloudfront.net/public/styles/large_slide_teaser/public/2018-09/D1C8427E-8A1B-4977-85E5-49898050DEE7.png?itok=BMnn7QG8)
EVOLVE SHORT-DAPT: Three-Month Outcomes on Dual Antiplatelet Therapy in a High Bleeding Risk Population Treated With a Bioresorbable Polymer-Based Drug-Eluting Stent | tctmd.com
![Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0002870318302461-gr1.jpg)
Rationale and design of the EVOLVE Short DAPT Study to assess 3-month dual antiplatelet therapy in subjects at high risk for bleeding undergoing percutaneous coronary intervention - ScienceDirect
![Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent - Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -](https://ars.els-cdn.com/content/image/1-s2.0-S0002870320302751-gr2.jpg)
Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent -
![SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal SAFETY OF ABBREVIATED DAPT IN HIGH BLEEDING RISK PATIENTS ON ANTICOAGULANTS OR AGE ≥75 YEARS AFTER PCI WITH THE SYNERGY STENT: A SUBGROUP ANALYSIS OF THE EVOLVE SHORT DAPT STUDY | Journal](https://www.jacc.org/cms/asset/08a80e15-6f4a-4e9c-8d8b-c47c239e64d8/s0735-1097(20)31861-1.fp.png)